Genocea Biosciences Inc. | Ownership
Companies that own Genocea Biosciences Inc.
BVF Partners LP
5,265,000
6.08%
265,000
0.23%
06/30/2018
Ghost Tree Capital LLC
3,525,000
4.07%
3,525,000
0.62%
06/30/2018
The Vanguard Group, Inc.
2,116,893
2.44%
-1,695
0%
06/30/2018
Alyeska Investment Group LP
1,603,085
1.85%
-231,719
0.01%
06/30/2018
Millennium Management LLC
853,385
0.99%
853,385
0%
06/30/2018
Ergoteles LLC
400,899
0.46%
400,899
0.01%
06/30/2018
Morgan Stanley & Co. LLC
300,349
0.35%
118,101
0%
06/30/2018
BlueCrest Capital Management (UK) LLP
285,662
0.33%
285,662
0.01%
06/30/2018
DRW Securities LLC
240,000
0.28%
240,000
0.01%
06/30/2018
Element Capital Management LLC
233,776
0.27%
233,776
0%
06/30/2018
| Address |
Cambridge Discovery Park
Cambridge Massachusetts 02140
United States
|
|
Employees
|
- |
| Website |
http://www.genocea.com |
| Updated |
07/08/2019 |
| Genocea Biosciences engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. |
